Balancing Total Intravenous Anesthesia and Inhalant Anesthesia in Horses

Total Page:16

File Type:pdf, Size:1020Kb

Load more

IN-DEPTH: ANESTHESIA AND PAIN MANAGEMENT Balancing Total Intravenous Anesthesia and Inhalant Anesthesia in Horses Ann E. Wagner, DVM, MS, Diplomate ACVA, ACVP Author’s address: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523; e-mail: [email protected]. © 2009 AAEP. 1. Introduction anesthesia are often smoother and more controlled 5 Intravenous drugs such as chloral hydrate, pento- than recoveries from inhalant anesthesia. Other barbital, and thiamylal were once commonly used advantages of TIVA include the minimal equipment required compared with inhalant anesthesia and for general anesthesia of horses but were often as- 6 sociated with prolonged or violent recover- potentially reduced stress. The development of re- ␣ ies. When inhalant anesthetics such as halothane versible or shorter-acting drugs such as 2 agonists, were introduced in the 1960s, the use of IV drugs for ketamine, and propofol has facilitated the use of 1 TIVA for longer procedures than previously consid- maintenance of anesthesia became less common. 7 In recent years, interest in IV anesthetic techniques ered safe. has been renewed, both by recognition of the rela- This article will review the current state of TIVA in horses, as well as how certain IV sedatives, anes- tively high risk of morbidity or mortality with inhal- thetics, and analgesics are being used to supplement ant techniques and by the development of injectable and improve inhalant anesthesia. drugs with fewer undesirable side effects and poten- tially improved recovery characteristics.2 2. Short-Term IV Anesthesia (≤20 min) In 2002, a large, multi-center prospective study In the United States, the most common technique reported peri-anesthetic mortality for horses to be used for short-term IV anesthesia is xylazine seda- 0.9% (1 death per 111 anesthetized horses).3 tion followed by ketamine induction, with or without Subsequently, one individual equine hospital re- diazepam for improved muscle relaxation. Xyla- ported a much lower mortality rate of 0.12–0.24% (1 zine-ketamine or xylazine-diazepam-ketamine pro- death per 417–833 cases).4 In the multi-center vides an average of 16 min of surgical anesthesia, study, anesthesia induced and maintained using with recovery to standing in ϳ25–32 min.8–10 It only IV drugs (total intravenous anesthesia [TIVA]) has been suggested that duration of surgical anes- was reported to be associated with a lower risk of thesia is longest in grade horses and shorter in Thor- death (0.3%, or 1 death per 321 cases) than anesthe- oughbreds.9 Most equine practitioners find both sia induced with IV drugs and maintained with in- induction and recovery with this drug regimen to be halant anesthesia.3 Recoveries from short-term IV satisfactory and reasonably safe. For good quality NOTES AAEP PROCEEDINGS ր Vol. 55 ր 2009 7 IN-DEPTH: ANESTHESIA AND PAIN MANAGEMENT Table 1. Adjuncts for Improved Quality of Anesthesia Listed below are suggested adjuncts for improving quality of anesthesia in horses that are too light or too tense after an ␣-2 agonist ϩ ketamine Ϯ diazepam induction and do not respond sufficiently to additional increments of ␣-2 agonist or ketamine Systemically administered drugs Thiopental ϳ1–2 mg/kg ͓5–10 ml of 10% thiopental͔ IV (augments CNS depression and muscle relaxation) Guaifenesin ϳ25–50 mg/kg ͓250–500 ml of 5% guaifenesin͔ IV (augments muscle relaxation only) Butorphanol ϳ0.01–0.02 mg/kg ͓0.5–1 ml͔ augments analgesia (more noticeable during IV anesthesia than during gas anesthesia) Locally or regionally administered drugs Castration Lidocaine infiltration of testicle Ϯ spermatic cord augments analgesia, improves cremaster relaxation, and prolongs surgical anesthesia time 15–20 ml 2% lidocaine injected directly into each testicle; some surgeons inject additional 5 ml into spermatic cord also Wounds Specific nerve blocks if applicable (digital, etc.) Perilesional infiltration with lidocaine Eye Specific nerve blocks if applicable Topical anesthetic on globe of surgical anesthesia, it is important to ensure that Thiopental, once the “gold standard” of anesthetic sedation and muscle relaxation are adequate; there- induction agents, is no longer commonly used for fore, in general, a higher dose of xylazine (1.1 mg/kg short-term anesthesia in horses. Although with or ϳ500 mg per 450-kg horse) than would typically appropriate premedication such as xylazine, thio- be used for standing sedation is recommended. Ad- pental inductions are quite predictable and smooth, ditional methods for improving muscle relaxation recoveries from short-term thiopental anesthesia and quality of IV anesthesia are listed in Table 1. tend to be somewhat uncoordinated.10 In addition, Although xylazine is the most common pre-medi- thiopental can be very irritating if accidentally in- cation in the United States, other ␣2 agonists may jected perivascularly, and the volume typically re- be used and may afford a slightly longer anesthesia quired to anesthetize a 450-kg horse (ϳ27 ml of 10% time. For example, detomidine (0.02 mg/kg, IV) fol- solution) makes perivascular injection a consider- lowed by ketamine (2.2 mg/kg, IV) produced recum- able risk, unless an IV catheter is in place. bency of slightly longer duration (average, 27 min) Interestingly, results of a controlled study sug- than xylazine (1.1 mg/kg, IV) and ketamine (2.2 gested that thiopental produced better-quality in- mg/kg, IV) (average, 23 min). However, muscle re- ductions than did ketamine and that combining laxation during anesthesia and recovery quality either ketamine or thiopental in various proportions were both slightly less satisfactory with detomidine- with propofol improved both induction and recovery ketamine than with xylazine-ketamine.11 quality.10 Propofol is an induction agent that has Romifidine is a newer ␣2 agonist associated with a become extremely popular both in humans and in longer duration and purportedly less ataxia than small animals, with generally smooth inductions xylazine. Both of these characteristics could be and particularly rapid and smooth recoveries, with beneficial for short-term IV anesthesia. A compar- none of the residual “hangover” often associated ison of romifidine (0.1 mg/kg, IV) to xylazine (1.1 with other anesthetics. In the equine study, com- mg/kg, IV), in combination with diazepam and ket- binations of 1⁄4 induction dose of propofol with 3⁄4 amine, showed that both regimens produced excel- induction dose of ketamine or thiopental produced lent quality anesthesia, with good induction and the smoothest inductions. However, the best-qual- recovery quality, and good muscle relaxation. The ity recoveries were achieved by combining 3⁄4 dose of romifidine combination produced about 5 additional propofol with 1⁄4 dose of ketamine or thiopental. min of surgical anesthesia (21 min) compared with One might then think that combining 1⁄2 dose of the xylazine combination (16 min). Recovery re- propofol with 1⁄2 dose of the others would result in quired about 44 min for the romifidine group com- both excellent inductions and excellent recoveries, 8 pared with 32 min for the xylazine group. and indeed, the “1⁄2-1⁄2” combinations did result in Butorphanol has been used as an adjunct for IV both induction and recovery quality that appeared to anesthesia. A comparison of xylazine-ketamine or be slightly better than either ketamine or thiopental detomidine-ketamine, with and without the addition alone.10 of butorphanol (0.04 mg/kg, IV, or 18 mg per 450-kg Unfortunately, there are issues related to propofol horse), suggested that butorphanol may improve administration in horses that detract from its use- muscle relaxation and surgical conditions and pro- fulness as a sole induction agent. Inductions by long recumbency time slightly.11 propofol alone may be quite violent, with paddling of 8 2009 ր Vol. 55 ր AAEP PROCEEDINGS IN-DEPTH: ANESTHESIA AND PAIN MANAGEMENT the limbs and uncoordinated muscle activity.12 pared by adding 4 ml of ketamine (100 mg/ml) and 1 Premedication with either xylazine or detomidine ml of detomidine (10 mg/nl) to reconstitute a 5-ml does not prevent excitatory behavior and muscle bottle of tiletamine-zolazepam. Horses were first activity.13 With the currently available propofol sedated with xylazine 0.44 mg/kg, IV (ϳ200 mg for a concentration of 10 mg/ml, the required induction dose 450-kg horse), and the combination TZKD was ad- (2 mg/kg) for a typical horse is nearly 100 ml, making ministered at 3 ml/450 kg, IV. This volume re- it inconvenient and time consuming to administer. sulted in individual drug doses of tiletamine- Respiratory depression may be profound and may ne- zolazepam at 0.67 mg/kg, ketamine at 0.53 mg/kg, cessitate assisted ventilation.12,13 Despite its reputa- and detomidine 0.013 mg/kg. The authors reported tion for rapid recoveries in most species, a single that advantages of this combination included the induction dose of propofol in horses (after xylazine small volume of drug to administer, predictable and premedication) is associated with slightly longer times rapid induction, good muscle relaxation and analge- to standing (ϳ33 min) than a single dose of ketamine sia that lasted longer than that associated with xy- (ϳ25 min).10,13 lazine-ketamine, and acceptable cardiorespiratory The use of tiletamine-zolazepam, another option values. All horses stood satisfactorily in two or for induction of anesthesia of horses, was first de- fewer attempts within 40 min after induction.15 scribed 20 yr ago.14 Tiletamine is a dissociative anesthetic similar to ketamine, and zolazepam is a 3. TIVA (>20 min) benzodiazepine similar to diazepam. Tiletamine When a procedure requires Ͼ15–20 min, surgical and zolazepam are marketed in the United States as anesthesia can be prolonged by administering addi- the 50:50 combination Telazol,a formulated as a tional IV anesthetics, either as intermittent boluses powder that must be reconstituted before use.
Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics

    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical

    The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical

    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
  • Serum Progesterone Concentrations in Cows Receiving Embryo Transfers J

    Serum Progesterone Concentrations in Cows Receiving Embryo Transfers J

    Serum progesterone concentrations in cows receiving embryo transfers J. F. Hasler, R. A. Bowen, L. D. Nelson and G. E. Seidel, Jr Animal Reproduction Laboratory, Colorado State University, Fort Collins, Colorado 80523, U.SA. Summary. Progesterone concentrations in systemic blood were determined by radio- immunoassay in crossbred cattle used as recipients in an embryo transfer pro- gramme. An embryo was transferred surgically to the uterine horn of 528 females which were in oestrus within one half-day of the donor. Jugular blood was obtained at the time embryos were transferred (3\p=n-\7days after oestrus) and again from most females between Days 9 and 14. Pregnancy was determined by rectal palpation 45\p=n-\ 65 days after oestrus. There were no significant differences between serum pro- gesterone levels of females which remained pregnant and those which did not. Out of 177 pregnant recipients, none had serum progesterone levels <0\m=.\5ng/ml on Days 10, 11, or 12 but in 8, values were <1\m=.\0ng/ml. Blood samples were also taken on Days 20, 21, or 22 from 113 of these recipients. The mean \m=+-\s.e.m. concentration of progesterone in the pregnant females (5\m=.\14\m=+-\0\m=.\34ng/ml) was significantly higher (P < 0\m=.\001)than in the non-pregnant females (1\m=.\17\m=+-\0\m=.\25ng/ml). The correlation coefficients between progesterone levels on Days 3, 4, 5 or 6 and 10\p=n-\12ranged from 0\m=.\18to 0\m=.\37(all P < 0\m=.\02).Progesterone levels were not related to length of the previous cycle, the time of day an animal was first noticed in oestrus or the side of the corpus luteum.
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • INTRAVENOUS ANAESTHESIA Dr

    INTRAVENOUS ANAESTHESIA Dr

    INTRAVENOUS ANAESTHESIA Dr. SK Sharma, Associate Professor General anaesthesia: It is the controlled, reversible intoxication of CNS producing unconsciousness with complete loss of sensory as well as motor reflexes. The common methods to induce GA in animals are by using inhalation and intravenous anaesthesia. The other not so common methods are oral. Per rectal, intramuscular, intra peritoneum etc. However out of these methods the most preferred method is intravenous anaesthesia. Intravenous anaesthesia: Intravenous anaesthesia in veterinary practice is primarily used for the induction of anaesthesia which is subsequently maintained by inhalation anaesthesia in small animals. However in large animals intravenous anaesthesia is mostly used for both induction as well as maintenance of anaesthesia. Advantages: 1. Easiness in administration. 2. Produces surgical anaesthesia with speed and pleasantness. 3. No sophisticated facilities are required as for inhalation anaesthesia. 4. Requires minimum equipment. 5. Economical Disadvantages: 1. Recovery depends upon the ability of the animal to redistribute, metabolize and excrete the anaesthetic drug. Very important in sick and debilitatedDr. animals. SK Sharma 2. Depth of anaesthesia cannot be decreased quickly unless you have an antagonist. 3. Recovery period may be longer depending upon the health status of the animal and the drug used. 4. Characteristic excitement and premature attempts to stand during recovery may be dangerous sometimes. 5. Long procedures can lead to severe physiological changes in the patient. 6. Oxygen and assisted controlled ventilation may not be available during emergency. 2 RUMONANTS ARE POOR SUBJECTS FOR INTRAVENOUS ANAESTHESIA. WHY? The ruminants are considered as poor subjects for general anaesthesia by any method because of many reasons as listed below: 1.
  • Physiological Factors Affecting Ovine Uterine Estrogen and Progesterone Receptorconcentrations Redacted for Privacy Abstract Approved: W-A Fredrick Stormshak

    Physiological Factors Affecting Ovine Uterine Estrogen and Progesterone Receptorconcentrations Redacted for Privacy Abstract Approved: W-A Fredrick Stormshak

    AN ABSTRACT OF THE THESIS OF Patrice L. Prater for the degree of Master ofScience in Animal Science presented on November 14. 1990 Title: Physiological Factors Affecting Ovine Uterine Estrogen and Progesterone ReceptorConcentrations Redacted for Privacy Abstract Approved: w-A Fredrick Stormshak Two experiments were conducted todetermine whether in ewes uterine concentrationsof estrogen and progesterone receptors are affected by the presence of aconceptus or by the hormonal milieu associated withextremes in photoperiod to which ewes are exposed. In Exp.1, nine mature ewes were unilaterally ovariectomized by removing an ovary bearing the corpusluteum (CL). The ipsilateral uterine horn wasligated at the external bifurcation and a portion of theanterior ipsilateral uterine horn was removed and assayed forendometrial nuclear and cytosolic concentrations of estrogenreceptor (ER) and progesterone receptor (PR) by exchange assays. After a recovery estrous cycle, ewes werebred to a fertile ram. On day 18 of gestation a 10 ml jugular bloodsample was collected for measurement of serum concentrationsof estradiol -178 (E2) and progesterone by radioimmunoassay. Ewes were relaparotomized on day 18 and the remaining uterine tissue was removed. Endometrium from both the pregnant and nonpregnant uterine horn was assayed for nuclear and cytosolic ER and PR concentrations. Nuclear and cytosolic ER concentrations on day 10 of the cycle were greater than in endometrium of gravid and nongravid uterine horns on day 18 of gestation (p<.01). Endometrial nuclear PR levels were also greater on day 10 of the cycle than in the pregnant (p<.05) and nonpregnant horn (p<.01) on day 18 of gestation. There were no differences in nuclear and cytosolic ER and PR concentrations between the pregnant and nonpregnant uterine horn on day 18.
  • The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest

    The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest

    University of New Orleans ScholarWorks@UNO University of New Orleans Theses and Dissertations Dissertations and Theses 5-21-2004 The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest Donna Neumann University of New Orleans Follow this and additional works at: https://scholarworks.uno.edu/td Recommended Citation Neumann, Donna, "The Design and Synthesis of Novel Barbiturates of Pharmaceutical Interest" (2004). University of New Orleans Theses and Dissertations. 1040. https://scholarworks.uno.edu/td/1040 This Dissertation is protected by copyright and/or related rights. It has been brought to you by ScholarWorks@UNO with permission from the rights-holder(s). You are free to use this Dissertation in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in University of New Orleans Theses and Dissertations by an authorized administrator of ScholarWorks@UNO. For more information, please contact [email protected]. THE DESIGN AND SYNTHESIS OF NOVEL BARBITURATES OF PHARMACEUTICAL INTEREST A Dissertation Submitted to the Graduate Faculty of the University of New Orleans in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Chemistry by Donna M. Neumann B. A. University of New Orleans, 2000 May 2004 Dedicated to: My daughter, Madeline Megan Jenkins ii ACKNOWLEDGEMENTS I would like to express my utmost gratitude to my advisor, Professor Branko S.
  • Akhtar Saeed Medical and Dental College, Lhr

    Akhtar Saeed Medical and Dental College, Lhr

    STUDY GUIDE PHARMACOLOGY 3RD YEAR MBBS 2021 AKHTAR SAEED MEDICAL AND DENTAL COLLEGE, LHR 1 Table of contents s.No Topic Page No 1. Brief introduction about study guide 03 2. Study guide about amdc pharmacology 04 3. Learning objectives at the end of each topic 05-21 4. Pharmacology classifications 22-59 5. General pharmacology definitions 60-68 6. Brief introduction about FB PAGE AND GROUP 69-70 7. ACADEMIC CALENDER (session wise) 72 2 Department of pharmacology STUDY GUIDE? It is an aid to: • Inform students how student learnIng program of academIc sessIon has been organized • help students organIze and manage theIr studIes throughout the session • guIde students on assessment methods, rules and regulatIons THE STUDY GUIDE: • communIcates InformatIon on organIzatIon and management of the course • defInes the objectIves whIch are expected to be achIeved at the end of each topic. • IdentIfIes the learning strategies such as lectures, small group teachings, clinical skills, demonstration, tutorial and case based learning that will be implemented to achieve the objectives. • provIdes a lIst of learnIng resources such as books, computer assIsted learning programs, web- links, for students to consult in order to maximize their learning. 3 1. Learning objectives (at the end of each topic) 2. Sources of knowledge: i. Recommended Books 1. Basic and Clinical Pharmacology by Katzung, 13th Ed., Mc Graw-Hill 2. Pharmacology by Champe and Harvey, 2nd Ed., Lippincott Williams & Wilkins ii. CDs of Experimental Pharmacology iii. CDs of PHARMACY PRACTICALS iv. Departmental Library containing reference books & Medical Journals v. GENERAL PHARMACOLOGY DFINITIONS vi. CLASSIFICATIONS OF PHARMACOLOGY vii.
  • Administrative Records, Texas Department of Criminal Justice

    Administrative Records, Texas Department of Criminal Justice

    Consistent with the terms of the Court’s May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug’s supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA’s review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas’s redactions that are over-broad or otherwise improper, we will work with Texas’s counsel to revise the redactions in the record. MISCELLANEOUS FDA 568 DOCUMENT#: VERSION#: DIOP PROCEDURE ~L ORO-DIOP- 2.00 FOOD & DRUG ADMINISTRATION .008 I OFFICE OF REGULATORY AFFAIRS PAGE 1 OF 4 TITLE: EFFECTIVE DATE: PROCESSING OF SODIUM THIOPENTAL ENTRIES 4/16/2012 Sections included in this document 1. Purpose 2. Scope 3. Responsibility 4. Background 5. References 6. Procedure 7. Definitions/Glossary 8. Records 9. Supporting Documents 10. Contact Information 11.Attachments Document History and Change History 1. Purpose Pending litigation, this procedure provides instructions on the handling of shipments of Sodium Thiopental by Districts and the responsibility of DIOP in the processing of Sodium Thiopental entries. Districts should disseminate this information to all pertinent staff handling these entries.
  • FDA Briefing Document November 15, 2018

    FDA Briefing Document November 15, 2018

    FDA Briefing Document Anesthetic and Analgesic Drug Products Advisory Committee Meeting November 15, 2018 DISCLAIMER STATEMENT The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought background information related to assessment of opioid analgesic sparing outcomes in clinical trials of acute pain and the need to focus on the development of opioid sparing and opioid replacement drugs, which have potential to reduce the need for and use of opioid analgesics, to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered. The final determination may be affected by issues not discussed at the advisory committee meeting. FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Anesthetic and Analgesic Drug Products Advisory Committee Meeting November 15, 2018 Table of Contents Background Materials Page 1 Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Director 1 Memorandum (Dr. Hertz) 2 Background information for Opioid Sparing 3 3 Appendix 1.
  • Guidance for Ideal Selection Tiffany Sia, MD; Hye-Chun Hur, MD, MPH

    Guidance for Ideal Selection Tiffany Sia, MD; Hye-Chun Hur, MD, MPH

    MDEDGE.COM/OBGYN | VOL 32, NO 10 | OCTOBER 2020 Society of Gynecologic Surgeons Annual Meeting Highlights Issue “Elective” should not be a descriptor for important ObGyn procedures Robert L. Barbieri, MD Update on contraception A member of the Network SPECIMEN RETRIEVAL BAGS Guidance for ideal selection Tiffany Sia, MD; Hye-Chun Hur, MD, MPH Work-life balance in gyn surgery Urethral bulking agents for SUI Should we abandon breast cancer screening for average-risk women in their 40s? only at mdedge.com/obgyn Optimizing coordination for dense breast screening p. 20 Follow us on Facebook and Twitter Improve Recovery After C-Section With Long-Lasting, Non-Opioid Pain Control Multimodal pain management with EXPAREL provided significantly better pain control after C-section vs multimodal protocols alone1,2 and… REDUCED REDUCED time REDUCED 52% postsurgical to ambulation vs hospital LOS by 1 day opioid use* (MED) over 12 multimodal protocol day (P<0.001); 2.9 days (n=97) 72 hours vs standard bupivacaine hours without EXPAREL 1 vs 3.9 days (n=89)1‡ TAP block (P=0.0117)2† (P<0.001)1‡ Improve clinical and economic outcomes. Learn more at www.EXPAREL.com/OBGyn LOS, length of stay; MED, morphine equivalent dose; TAP, transversus abdominis plane. *The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials. †A prospective, 13-site, multicenter, randomized clinical trial of 186 patients who underwent a C-section with a multimodal pain management protocol, including a TAP block using either 20 mL EXPAREL 266 mg, 20 mL 0.25% bupivacaine HCl, and 20 mL normal saline (30 mL volume on each side) for a total volume of 60 mL; or 20 mL 0.25% bupivacaine HCl and 40 mL normal saline (30 mL volume on each side) for a total volume of 60 mL.2,3 ‡Single-center retrospective trial of 201 patients who underwent C-section with either a multimodal pain management protocol including a TAP block with 20 mL EXPAREL 266 mg, 30 mL 0.25% bupivacaine HCI, and 30 mL normal saline; or a multimodal pain management protocol alone.